ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 372

Arterial Involvement in Erdheim-Chester Disease: A Retrospective Cohort Study

Michel Villatoro-Villar1, Michael Bold2, Kenneth J. Warrington3, Cynthia S. Crowson4, Gaurav Goyal5, Mithun Shah5, Ronald Go5 and Matthew J. Koster1, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Radiology, Mayo Clinic, Rochester, MN, 3Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN, 4Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 5Hematology, Mayo Clinic, Rochester, MN

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Erdheim-Chester disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster I: Checkpoint Inhibitors, Retroperitoneal Fibrosis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Erdheim-Chester disease (ECD) is a rare histiocytosis of the “L” (Langerhans) group with multisystem involvement that can affect the large and medium sized arteries mimicking vasculitis. Aortic involvement is common but the frequency and outcome of aortic branch vessel abnormalities are less well described.

Methods: Patients diagnosed with ECD from January 1, 1998 to July 31, 2016 were retrospectively identified. Images containing information of arterial involvement within six months of diagnosis were considered baseline and compared to last follow-up studies. Two physicians independently reviewed the studies to evaluate for presence of abnormalities attributable to ECD. Age and sex adjusted logistic regression models were used to examine associations between patient characteristics and vessel involvement at baseline.

Results: Among a cohort of 64 patients with ECD, 63 had baseline imaging of vascular structures. ECD involvement of at least one segment of the aorta was observed in 56%. Abnormalities were also observed in aortic arch branches (26%), visceral branch arteries (40%), iliofemoral arteries (31%), coronary (5%) and pulmonary (3%) arteries. Perinephric fibrosis was strongly associated with the identification of abnormalities in the thoracic aorta [OR 4.92 (1.54, 15.75); p=0.007], abdominal aorta [OR 7.57 (2.28, 25.07); p=0.001] and visceral branch arteries [OR 6.05 (1.52, 24.03); p=0.01] but not pelvic/lower extremity arteries.

A total of 47 patients had follow-up imaging of arterial structures. The majority of arterial segments affected at baseline did not have significant radiographic change during the follow-up evaluation. Partial response was observed in 11% of patients with baseline abnormalities seen in the infra-renal abdominal aorta and 6% of patients with baseline aortic arch, descending thoracic aorta, and supra-renal abdominal aorta involvement, respectively. The remainder of arterial segments had partial response detected at a frequency of less than 5%. Complete normalization of arterial abnormalities at follow-up was only observed in 9% or less of arterial segments involved at baseline. Development of arterial involvement after diagnosis in patients with normal baseline arteries was similarly infrequent but occurred most often in the pulmonary arteries (11%), celiac artery (9%), right iliac (7%), left iliac (7%) and right femoral (5%). Eight patients required intervention with arterial endovascular stenting or bypass. At last follow-up 12 (19%) patients were deceased. Of the 9 patients for which cause of death was known, only 3 patients died from cardiovascular causes.

Conclusion: Aortic and aortic branch vessel abnormalities are frequently observed in patients with ECD and are often asymptomatic. Partial and/or complete resolution of arterial findings is uncommon.


Disclosure: M. Villatoro-Villar, None; M. Bold, None; K. J. Warrington, GlaxoSmithKline, 2,Eli Lilly and Co., 2,Sanofi, 5; C. S. Crowson, None; G. Goyal, None; M. Shah, None; R. Go, None; M. J. Koster, None.

To cite this abstract in AMA style:

Villatoro-Villar M, Bold M, Warrington KJ, Crowson CS, Goyal G, Shah M, Go R, Koster MJ. Arterial Involvement in Erdheim-Chester Disease: A Retrospective Cohort Study [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/arterial-involvement-in-erdheim-chester-disease-a-retrospective-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/arterial-involvement-in-erdheim-chester-disease-a-retrospective-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology